
Helping keep antibiotics effective for generations to come
Around the world, once-treatable infections are becoming life-threatening again as bacteria become increasingly resistant to antibiotics.
Teva is showing how education and technology can help drive change – supporting healthcare professionals to prescribe antibiotics appropriately and raising awareness to help patients better understand and use them responsibly.
Key takeaways:
|
Antimicrobial resistance (AMR) is a growing global health challenge. This makes some bacterial infections increasingly difficult to treat. |
|
Responsible antibiotic use matters. Education and timely information can support appropriate prescribing and help patients understand when and how antibiotics should be used. |
|
Addressing AMR goes beyond prescribing. Community education, antimicrobial stewardship and responsible manufacturing also have a role in helping protect the effectiveness of antibiotics. |
Since Alexander Fleming discovered penicillin in 1928, antibiotics have transformed our ability to treat bacterial infections and helped shape modern medicine. They have helped make routine surgery, caesarean sections, organ transplants and cancer chemotherapy much safer.
But their effectiveness can't be taken for granted. When bacteria are exposed to an antibiotic, the most vulnerable are eliminated while those that survive can multiply and adapt. As antibiotics are used more frequently, especially when they are unnecessary or used incorrectly, bacteria have more opportunities to become resistant and spread.
Bacterial AMR occurs when bacteria no longer respond to antibiotics, making infections more difficult to treat and increasing the risk of severe illness and disease spread.
In 2021, the WHO reported 4.7 million deaths could be associated with AMR. By 2023, 1 in 6 laboratory-confirmed bacterial infections worldwide was resistant to antibiotics, and it was estimated that 39 million deaths could be directly attributable to bacterial AMR between 2025 and 2050.
How Teva is helping protect antibiotics
As one of the world's major suppliers of medicine, Teva has an important role to play. In 2025 alone, our anti-infectives medicines reached ~92 million patients globally. That scale brings a responsibility to help protect these essential medicines, from how they are manufactured to how they are prescribed and used.
Recognizing the growing threat of antibiotic resistance, we took action to help raise awareness about responsible antibiotic use among healthcare professionals and patients. We set a goal to educate 40,000 healthcare professionals and 400,000 patients on appropriate antibiotic use by 2026.
We focused on key areas where education could make a difference: supporting appropriate prescribing, improving patients’ understanding of when and how antibiotics should be used, and reinforcing responsible use at key points in their care.
By the end of 2026, we had exceeded our targets:
|
~65,597 healthcare professionals reached |
|
~435,864 patient interactions achieved |
Here are four ways we turned that commitment into action and impact:
The moment a patient collects an antibiotic from the pharmacy, an important opportunity arises to reinforce how it should be taken, why appropriate use matters and how to dispose of it responsibly.
In 2024, Teva ran one-year program exploring how digital technology could increase antibiotic awareness and appropriate use in Germany.
Pop-up messages were integrated into dispensing systems in around 11,000 pharmacies, supporting pharmacists in conversations with patients about appropriate antibiotic use.

More than 388,000 patient interactions were triggered for pharmacists via digital messages, with 77% saying the campaign materials were useful in helping improve patient compliance.
A further 82,000 SMS messages were delivered directly to patients.
Analysis of prescription data showed encouraging changes in how antibiotics were used compared to the historical control data from the previous year:
|
4%* reduction in antibiotic switches |
|
13.8%* reduction in antibiotic escalations |
|
29%* reduction in amount of antibiotics per patient |
*compared to historical control group
These findings suggest that simple digital messaging can help reinforce appropriate antibiotic use as part of everyday healthcare interactions.
The decision to prescribe an antibiotic is a critical moment. Unnecessary antibiotic use is one of the key drivers of antimicrobial resistance, making it increasingly important that healthcare professionals have the right information available at the point of care.
We decided to again use technology to put that information directly into existing clinical workflows.
This led to a one-year program in Kenya between April 2025-2026, where digital pop-up messages on appropriate antibiotic use reached 539 doctors across 170 practices through more than 15,000 alerts.
Real-world prescribing data* showed:
|
8% reduction in prescribing rate for upper respiratory tract infections |
|
6% increase in guideline-aligned prescribing for bacterial lower respiratory tract infections |

The digital campaign in Kenya also encouraged doctors to share information about antibiotic use during their consultation – directly reaching around 47,000 patients and dispelling common misconceptions, such as using antibiotics to treat colds or flu
We know driving awareness is critical, so we looked for more ways to reach patients by empowering people to lead change locally.
In 2026, Teva began supporting an Antimicrobial Stewardship Champions Program in collaboration with Commonwealth Pharmacists Association (CPA), bringing together 55 people in healthcare – 25 in the UK and 30 in South Africa. From hospital and community pharmacy to primary care, academia, public health, government and industry, each Champion can influence how antibiotics are understood and used in their own community.
Through training, mentoring and peer learning, Champions are building their expertise in antimicrobial stewardship alongside practical skills in leadership, advocacy and campaign planning. We are excited to see what they achieve – and how they help their communities.
Antimicrobial resistance can also develop when antibiotics enter the environment through agriculture, manufacturing and incorrect disposal.
As a responsible manufacturer, Teva focuses on managing antimicrobial discharges from our operations and reports annually on our progress. We are committed to achieving safe discharge levels (RQ <1) at 100% of applicable Teva sites by 2035. In 2025, 19 sites (73%) had already been confirmed as operating within our voluntary safe discharge limits, and we are also committed to assessing supplier sites.
To help drive progress across the industry, Teva was one of six companies to pilot the AMR Industry Alliance manufacturing discharge standard, and one of the first two to receive BSI certification for the responsible manufacturing of an antibiotic product.
Protect the antibiotics that protect us
There is no single solution to antimicrobial resistance.
Hand in hand with our commitment to manufacturing quality medicines responsibly, experience shows that awareness is an important part of driving change. By working with healthcare professionals, patients, partners, communities and our industry, we can help protect antibiotics, so they continue to protect people for generations to come.